Merck (NYSE: MRK) reported Q2 EPS of $2.13, $0.10 better than the analyst estimate of $2.03. Revenue for the quarter came in at $15.81 billion versus the consensus estimate of $15.87 billion.

GUIDANCE:

Merck sees FY2025 EPS of $8.87-$8.97, versus the consensus of $8.87. Merck sees FY2025 revenue of $64.3-65.3 billion, versus the consensus of $64.9 billion.

For earnings history and earnings-related data on Merck (MRK) click here.